Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jhKOgk
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jCvX3K via IFTTT
-
Abstract Purpose of Review Our goal is to summarize the airway disease literature since September 11, 2001 (9/11), focusing on studies pub...
-
Treatment effectiveness holds considerable importance in the association between service quality and satisfaction in medical service studies...
-
Vol.25 No.2 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1P7bHxT via IFTTT
-
Publication date: Available online 16 January 2017 Source: International Journal of Pediatric Otorhinolaryngology Author(s): Kaveh Karimn...
-
Daily Mail Sarah was diagnosed with the cancer that killed Steve Jobs Daily Mail The symptoms Sarah Smith experienced on and off for...
-
Omalizumab is a treatment for asthma that has a success rate of approximately 40% to 50%.1 Recent mechanistic studies have suggested that ba...
-
Understanding Head And Neck Cancers - The Southeast Sun ... The Southeast Sun (NAPSI)—According to the Centers for Disease Control an...
-
Abstract Background Henoch–Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involve...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου